A company still losing money with steady sales. Institutions are adding.
Going well
Pays a 6.9% dividend yield
Buying back shares: share count down 7.5% in 3 years
Watch out for
Losing money
Debt above equity: 1.7x
Money moves
No insider buying or selling in the last 30 days
Institutions added 6.5% to their holdings in the quarter ending June 2026 (201 bought, 180 sold)
Held by Ray Dalio (Bridgewater), Cathie Wood (ARK Invest)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$9.21-2.3% that day
Company value
$1.8B
Share price times all shares
Price vs sales
0.50x
No profit over the last year, so this compares value with sales instead
Dividend yield
6.9%
Yearly dividend as a share of today's price
Cash vs value
13%
Cash as a share of company value
Debt vs value
124%
Owes more than the whole company is worth
From XRAY's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26
$898.0M-4.1% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $3.6B, down 0.8% from the 12 months before. Over 5 years, sales grew about 2.0% a year.
What the price assumes
Your guesses, our math
Move the sliders to your own view of XRAY. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).
Sales in 5 years$3.5B
Profit in 5 years$346M
Price these guesses point to$28.84+213% vs $9.21 todayAbout +26% a year, before dividends
What today's price needs: with a 10% margin and a 15x P/E, sales could shrink about 21% a year for 5 years and still match today's price.
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.